An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Trial Profile

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs SAR 422459 (Primary)
  • Indications Stargardt disease
  • Focus Adverse reactions
  • Sponsors Oxford BioMedica; Sanofi
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Nov 2033 to 15 Mar 2034.
    • 11 Jul 2017 Planned primary completion date changed from 1 Nov 2033 to 15 Mar 2034.
    • 14 Oct 2016 Planned End Date changed from 1 Dec 2032 to 1 Nov 2033.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top